ClinicalTrials.gg
Active, not recruitingNCT06588153Updated May 27, 2026

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

A Phase 4 interventional study of Prolia® in Glucocorticoid-induced Osteoporosis, sponsored by Amgen. Active, not recruiting at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
28th of 64
102 · median 90
Started
2025
with 3 others
Phase 4
19 of 64
5 open now
Primary completion
2027-04
later than 8 of 10 live
Registered
58th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 28th largest by enrollment, is one of 4 that started in 2025, is one of 19 in phase 4, reaches primary completion later than 8 of the 10 other live ones, and was the 58th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the efficacy of Prolia® in improving bone mass density (BMD) of lumbar spine at month 12.

03

Conditions studied

  • Glucocorticoid-induced Osteoporosis

Browse trials for

Keywords

  • Prolia®
  • Denosumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has provided prior to initiation of any study-specific activities/procedures.
  • Male and female participants aged ≥ 18 years at the time of signing the informed consent.
  • Participants are receiving treatment at screening.
  • Participants who are ≥ 50 years of age at the time of screening will be required to have a T-score with:

    - a BMD value equivalent to a T-score ≤ -2.5 at the lumbar spine or total hip or femoral neck; OR

    - a BMD value equivalent to a T-score ≤ -1.0 at the lumbar spine or total hip or femoral neck AND a history of osteoporotic fracture.

  • Participants who are \< 50 years of age at the time of screening will be required to have a T-score with a BMD value equivalent to a T-score ≤ -1.0 at the lumbar spine or total hip or femoral neck AND have a history of osteoporotic fracture.
  • At least 2 lumbar vertebrae from L1 through L4 and 1 hip must be evaluable by dual-energy x-ray absorptiometry (DXA).
  • Adequate organ function, defined as follows:

    • Hematological function:

      1. ≥ 1 x 10\^9 /L
      2. count ≥ 100 x 10\^9 /L
      3. > 9 g/dL (90 g/L).
    • Coagulation function:

      1 (PT)/international normalized ratio (INR) and partial thromboplastin time or activated partial thromboplastin time ≤ 1.5 x (ULN). Participants on chronic anticoagulation therapy who do not meet the criteria above may be eligible to enroll at the investigator's discretion per local standard of care.

    • Renal function:

      1 Estimated based on Modification of Diet in Renal Disease (MDRD) calculation > 30 mL/min/1.73 m\^2.

    • Hepatic function:

      1. (AST), alanine aminotransferase (ALT), and alkaline phosphatase \< 3 x ULN
      2. Total (TBL) \< 1.5 x ULN.

Exclusion criteria

Exclusion Criteria

Disease Related

  • Received other osteoporosis treatment or bone-active treatment with:

    - prior use of bisphosphonate:

    1. bisphosphonate use within 1 year unless duration of oral bisphosphonates treatment \< 3 months use prior to screening
    2. administration of intravenous zoledronate within 2 years or intravenous bisphosphonate other than zoledronate within the last year.

      • fluoride or strontium for osteoporosis within the last 5 years
      • anabolic agents to include PTH or PTH derivatives within the last year
      • any prior use of products containing denosumab
  • Administration of any of the following treatments within 3 months of screening:

    - any selective estrogen receptor modulator (estrogen agonist antagonist)

    • tibolone
    • anabolic steroids
    • testosterone above normal replacement doses not on stable dose
    • systemic hormone replacement therapy not on stable dose
    • systemic hormonal not specified in the protocol or not on stable dose
    • calcitonin.
  • Other bone-active drugs including:

    • anti-convulsants (except benzodiazepines) and heparin (low molecular weight heparin is allowed)
    • chronic systemic ketoconazole, androgens, adrenocorticotropic hormone (ACTH), cinacalcet, aluminum, lithium, protease inhibitors, gonadotropin-releasing hormone agonists.
  • Any pretrial initiation of anti-inflammatory disease-modifying anti-rheumatic drug (DMARD) that is not consistent with the local Chinese label or guidelines.
  • Participant has an active infection or history of infections as follows:

    • any active infection for which systemic anti-infectives were used within 4 weeks prior to screening
    • a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to screening
    • recurrent or chronic infections or other active infection that, in the opinion of the investigator, might compromise the safety of the participant.

Other Medical Conditions

  • History of hyperthyroidism (stable on antithyroid therapy is allowed) when suggested by medical history
  • History of hypothyroidism (stable on thyroid replacement therapy is allowed) when suggested by medical history
  • History of hypo- or hyperparathyroidism
  • History of Addison's disease
  • History of osteomalacia
  • History of osteonecrosis of the jaw (ONJ)
  • History of tooth extraction or other dental surgery within the prior 6 months
  • Invasive dental work (per local oral surgeon's assessment) planned in the next 12 months
  • History of Paget's disease of bone
  • Other bone diseases which affect bone metabolism (e.g., osteopetrosis, osteogenesis imperfecta) (chart review)
  • Received any solid organ or bone marrow transplant
  • Known to have tested positive for , virus, surface antigen
  • Participants with a history of any cancer (cured basal cell or squamous cell cancers are allowed)

Prior/Concurrent Clinical Study Experience • Currently receiving treatment in another device or drug study, or less than 30 days or 5 half-lives, whichever is longer, since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.

Diagnostic Assessments

  • Abnormalities of the following per central laboratory reference ranges:

    - Vitamin D deficiency (25[OH] vitamin D level \< 20 ng/mL [\< 49.9 nmol/L]). Vitamin D replenishment will be permitted, and participants may be re-screened once.

    - Hypercalcemia.

    - Elevated transaminases ≥ 3.0 x .

    • Elevated TBL > 1.5 x ULN.
    • Albumin-adjusted serum calcium levels \< 8.5 mg/dL or > 10.5 mg/dL.

Other Exclusions

  • Female participants of unwilling to use protocol-specified method of contraception (see Appendix 5, Section 11.5) during treatment and for an additional 5 months after the last dose of Prolia®.
  • Female participants who are breastfeeding or who plan to breastfeed while on study through 5 months after the last dose of Prolia®.
  • Female participants planning to become pregnant while on study through 5 months after the last dose of Prolia®.
  • Female participants of childbearing potential with a positive pregnancy test assessed at Screening by a serum pregnancy test.
  • Participant has known sensitivity to any of the products or components to be administered during dosing.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant's and investigator's knowledge.
  • History or evidence of any other disorder, condition, or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Prolia®

    Participants with glucocorticoid-induced osteoporosis (GIOP) will receive Prolia® every 6 months (Q6M).

    Drug: Prolia®

Interventions

  • Subcutaneous (SC) injection in pre-filled syringe.

    Also known as: Denosumab

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Lumbar Spine BMD Percentage

    Time frame: At 12 months

Secondary outcomes

  1. Change from Baseline in C-terminal Telopeptide (CTx) Expression

    Time frame: At 3, 6, 9, and 12 months

  2. Change from Baseline in Procollagen Type 1 N-Telopeptide (P1NP) Expression

    Time frame: At 3, 6, 9, and 12 months

  3. Change from Baseline in Hip and Femoral Neck BMD Percentage

    Time frame: At 6 and 12 months

  4. Change from Baseline in Lumbar Spine BMD Percentage

    Time frame: At 6 months

  5. Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. An AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a treatment, combination product, medical device, or procedure. TEAEs are any event that occurred after the participant received study treatment. Serious AEs (SAEs) are defined as any untoward medical occurrence that, meets at least 1 of the following serious criteria: immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect.

    Time frame: Up to 12 months

07

Study locations

16 sites
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.

Of 65 phase 4 interventional studies under Osteoporosis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 75. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2024
First posted
Sep 19, 2024
StartActual
May 24, 2025
Primary completionEst.
Apr 27, 2027
CompletionEst.
Apr 27, 2027
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06588153
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
May 24, 2025
Primary completion
Apr 27, 2027 (estimated)
Completion
Apr 27, 2027 (estimated)
Last update
May 27, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion